Travere Therapeutics officer proposes 9-share sale

The notice also lists three sales during the past three months and May 28, 2025, as the Rule 10b5-1 plan adoption or instruction date.

Accepted by SEC EDGAR 04/14/2026 - 04:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) officer Christopher Cline reported a proposed sale of 9 common shares, with an aggregate market value of $369.63 and an approximate sale date of April 14, 2026. Cline acquired 9 shares of restricted stock from the issuer on April 10, 2026. The listed Rule 10b5-1 plan adoption or instruction date is May 28, 2025.

During the past three months, Cline reported sales of 65 shares on April 13, 2026, for gross proceeds of $1,875.25; 1,745 shares on February 4, 2026, for $56,165.62; and 7,242 shares on February 3, 2026, for $232,616.03.

Key Figures

Proposed shares for sale: 9 shares Aggregate market value: $369.63 Shares sold: 65 shares +5 more

8 metrics

Proposed shares for sale 9 shares Common stock; approximate sale date April 14, 2026

Aggregate market value $369.63 Proposed sale

Shares sold 65 shares April 13, 2026

Gross proceeds $1,875.25 Sale on April 13, 2026

Shares sold 1,745 shares February 4, 2026

Gross proceeds $56,165.62 Sale on February 4, 2026

Shares sold 7,242 shares February 3, 2026

Gross proceeds $232,616.03 Sale on February 3, 2026

Key Terms

Rule 10b5-1, Restricted Stock, Aggregate Market Value

3 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Restricted Stock financial

"Nature of Acquisition Transaction: Restricted Stock"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Aggregate Market Value financial

"Aggregate Market Value: 369.63"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TVTX shares did Christopher Cline propose to sell?

Christopher Cline reported a proposed sale of 9 common shares, with an aggregate market value of $369.63 and an approximate sale date of April 14, 2026.

What TVTX shares did Christopher Cline sell in the past three months?

He reported sales of 65 shares on April 13, 2026, for gross proceeds of $1,875.25; 1,745 shares on February 4, 2026, for $56,165.62; and 7,242 shares on February 3, 2026, for $232,616.03.

What Rule 10b5-1 date is listed for Christopher Cline?

The listed Rule 10b5-1 plan adoption or instruction date is May 28, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001943192
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive Suite 300 San Diego CALIFORNIA 92130
Phone	888-969-7879
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOPHER CLINE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9	369.63	92241550	04/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/10/2026	Restricted Stock	Issuer			9	04/10/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHRISTOPHER CLINE 3611 Valley Centre Drive Suite 300 San Diego CA 92130	COMMON	04/13/2026	65	1875.25
CHRISTOPHER CLINE 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	02/04/2026	1745	56165.62
CHRISTOPHER CLINE 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	02/03/2026	7242	232616.03

144: Remarks and Signature

Remarks
Date of Notice	04/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/28/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christopher Cline
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)